Best Practice & Research Clinical Haematology
Volume 19, Issue 4 , Pages 685-699 , December 2006

BL22 and lymphoid malignancies

  • Robert J. Kreitman, MD (Chief, Clinical Immunotherapy Section, Laboratory of Molecular Biology)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +1 301 496 6947; Fax: +1 301 576 3920.
  • Ira Pastan, MD (Chief, Laboratory of Molecular Biology)

References 

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA: A Cancer Journal for Clinicians. 2006;56:106–130
  2. Greenlee RT, Hill-Harmon MB, Murray T, et al. Cancer statistics, 2001. CA: A Cancer Journal for Clinicians. 2001;51:15–36
  3. Cheson BD. Monoclonal antibody therapy of chronic lymphocytic leukemia. Cancer Immunology, Immunotherapy. 2006;55:188–196
  4. Maloney DG. Immunotherapy for non-Hodgkin's lymphoma: monoclonal antibodies and vaccines. Journal of Clinical Oncology. 2005;23:6421–6428
  5. Foss F. Clinical experience with Denileukin Diftitox (ONTAK). Seminars in Oncology. 2006;33:11–16
  6. Williams DP, Snider CE, Strom TB, et al. Structure/function analysis of interleukin-2-toxin (DAB486-IL-2). Fragment B sequences required for the delivery of fragment A to the cytosol of target cells. The Journal of Biological Chemistry. 1990;265:11885–11889
  7. Endo Y, Mitsui K, Motizuki M, et al. The mechanism of action of ricin and related toxic lectins on eukaryotic ribosomes. The Journal of Biological Chemistry. 1987;262:5908–5912
  8. Yamaizumi M, Mekada E, Uchida T, et al. One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell. Cell. 1978;15:245–250
  9. Kreitman RJ, Pastan I. Making fusion toxins to target leukemia and lymphoma. In:  Francis GE,  Delgado C editor. Drug Targeting. Vol. 25:999 Riverview Dr/Ste 208/Totowa/NJ 07512-1165/USA: Humana Press Inc; 2000;p. 215–226
  10. Kreitman RJ, Pastan I. Purification and characterization of IL6-PE4E, a recombinant fusion of interleukin 6 with Pseudomonas exotoxin. Bioconjugate Chemistry. 1993;4:581–585
  11. Keppler-Hafkemeyer A, Kreitman RJ, Pastan I. Apoptosis induced by immunotoxins used in the treatment of hematologic malignancies. International Journal of Cancer. 2000;87:86–94
  12. Bird RE, Hardman KD, Jacobson JW, et al. Single-chain antigen-binding proteins. Science. 1988;242:423–426
  13. Huston JS, Levinson D, Mudgett-Hunter M, et al. Protein engineering of antibody binding sites: recovery of specific activity in an antidigoxin single-chain Fv analogue produced in Escherichia coli. Proceedings of the National Academy of Sciences of the United States of America. 1988;85:5879–5883
  14. Chaudhary VK, Queen C, Junghans RP, et al. A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin. Nature. 1989;339:394–397
  15. Kreitman RJ, Wilson WH, Robbins D, et al. Responses in refractory hairy cell leukemia to a recombinant immunotoxin. Blood. 1999;94:3340–3348
  16. Kreitman RJ, Wilson WH, White JD, et al. Phase I trial of recombinant immunotoxin Anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. Journal of Clinical Oncology. 2000;18:1614–1636
  17. Mansfield E, Chiron MF, Amlot P, et al. Recombinant RFB4 single-chain immunotoxin that is cytotoxic towards CD22-positive cells. Biochemical Society Transactions. 1997;25:709–714
  18. Hwang J, FitzGerald DJ, Adhya S, et al. Functional domains of Pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. coli. Cell. 1987;48:129–136
  19. Allured VS, Collier RJ, Carroll SF, et al. Structure of exotoxin A of Pseudomonas aeruginosa at 3.0 Angstrom resolution. Proceedings of the National Academy of Sciences of the United States of America. 1986;83:1320–1324
  20. Hessler JL, Kreitman RJ. An early step in Pseudomonas exotoxin action is removal of the terminal lysine residue, which allows binding to the KDEL receptor. Biochemistry. 1997;36:14577–14582
  21. Kounnas MZ, Morris RE, Thompson MR, et al. The α2-macroglobulin receptor/low density lipoprotein receptor-related protein binds and internalizes Pseudomonas exotoxin A. The Journal of Biological Chemistry. 1992;267:12420–12423
  22. Chiron MF, Fryling CM, FitzGerald DJ. Cleavage of Pseudomonas exotoxin and diphtheria toxin by a furin-like enzyme prepared from beef liver. The Journal of Biological Chemistry. 1994;269:18167–18176
  23. Fryling C, Ogata M, FitzGerald D. Characterization of a cellular protease that cleaves Pseudomonas exotoxin. Infection and Immunity. 1992;60:497–502
  24. Ogata M, Fryling CM, Pastan I, et al. Cell-mediated cleavage of Pseudomonas exotoxin between Arg279 and Gly280 generates the enzymatically active fragment which translocates to the cytosol. The Journal of Biological Chemistry. 1992;267:25396–25401
  25. McKee ML, FitzGerald DJ. Reduction of furin-nicked Pseudomonas exotoxin A: an unfolding story. Biochemistry. 1999;38:16507–16513
  26. Chaudhary VK, Jinno Y, FitzGerald D, et al. Pseudomonas exotoxin contains a specific sequence at the carboxyl terminus that is required for cytotoxicity. Proceedings of the National Academy of Sciences of the United States of America. 1990;87:308–312
  27. Kreitman RJ, Pastan I. Importance of the glutamate residue of KDEL in increasing the cytotoxicity of Pseudomonas exotoxin derivatives and for increased binding to the KDEL receptor. The Biochemical Journal. 1995;307:29–37
  28. Theuer C, Kasturi S, Pastan I. Domain II of Pseudomonas exotoxin A arrests the transfer of translocating nascent chains into mammalian microsomes. Biochemistry. 1994;33:5894–5900
  29. Theuer CP, Buchner J, FitzGerald D, et al. The N-terminal region of the 37-kDa translocated fragment of Pseudomonas exotoxin A aborts translocation by promoting its own export after microsomal membrane insertion. Proceedings of the National Academy of Sciences of the United States of America. 1993;90:7774–7778
  30. Carroll SF, Collier RJ. Active site of Pseudomonas aeruginosa exotoxin A. Glutamic acid 553 is photolabeled by NAD and shows functional homology with glutamic acid 148 of diphtheria toxin. The Journal of Biological Chemistry. 1987;262:8707–8711
  31. Li M, Dyda F, Benhar I, et al. Crystal structure of the catalytic domain of Pseudomonas exotoxin A complexed with a nicotinamide adenine dinucleotide analog: implications for the activation process and for ADP ribosylation. Proceedings of the National Academy of Sciences of the United States of America. 1996;93:6902–6906
  32. Jorgensen R, Merrill AR, Yates SP, et al. Exotoxin A-eEF2 complex structure indicates ADP ribosylation by ribosome mimicry. Nature. 2005;436:979–984
  33. Brinkmann U, Brinkmann E, Gallo M, et al. Cloning and characterization of a cellular apoptosis susceptibility gene, the human homologue to the yeast chromosome segregation gene CSE1. Proceedings of the National Academy of Sciences of the United States of America. 1995;92:10427–10431
  34. Buchner J, Pastan I, Brinkmann U. A method for increasing the yield of properly folded recombinant fusion proteins: single-chain immunotoxins from renaturation of bacterial inclusion bodies. Analytical Biochemistry. 1992;205:263–270
  35. Kreitman RJ, Hansen HJ, Jones AL, et al. Pseudomonas exotoxin-based immunotoxins containing the antibody LL2 or LL2-Fab' induce regression of subcutaneous human B-cell lymphoma in mice. Cancer Research. 1993;53:819–825
  36. Mansfield E, Pastan I, FitzGerald DJ. Characterization of RFB4-Pseudomonas exotoxin A immunotoxins targeted to CD22 on B-cell malignancies. Bioconjugate Chemistry. 1996;7:557–563
  37. Theuer CP, Kreitman RJ, FitzGerald DJ, et al. Immunotoxins made with a recombinant form of Pseudomonas exotoxin A that do not require proteolysis for activity. Cancer Research. 1993;53:340–347
  38. Ghetie M-A, Richardson J, Tucker T, et al. Antitumor activity of Fab' and IgG-anti-CD22 immunotoxins in disseminated human B lymphoma grown in mice with severe combined immunodeficiency disease: effect on tumor cells in extranodal sites. Cancer Research. 1991;51:5876–5880
  39. Ghetie M-A, Tucker K, Richardson J, et al. The antitumor activity of an anti-CD22 immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-CD19 antibody or an anti-CD19 immunotoxin. Blood. 1992;80:2315–2320
  40. Vitetta ES, Stone M, Amlot P, et al. Phase I immunotoxin trial in patients with B-cell lymphoma. Cancer Research. 1991;51:4052–4058
  41. Amlot PL, Stone MJ, Cunningham D, et al. A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood. 1993;82:2624–2633
  42. Sausville EA, Headlee D, Stetler-Stevenson M, et al. Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: a phase I study. Blood. 1995;85:3457–3465
  43. Senderowicz AM, Vitetta E, Headlee D, et al. Complete sustained response of a refractory, post-transplantation, large B-cell lymphoma to an anti-CD22 immunotoxin. Annals of Internal Medicine. 1997;126:882–885
  44. Messmann RA, Vitetta ES, Headlee D, et al. A phase I study of combination therapy with immunotoxins IgG-HD37- deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma. [In Process Citation] Clinical Cancer Research. 2000;6:1302–1313
  45. Mansfield E, Amlot P, Pastan I, et al. Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors. Blood. 1997;90:2020–2026
  46. Kreitman RJ, Wang QC, FitzGerald DJP, et al. Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by Cynomolgus monkeys. International Journal of Cancer. 1999;81:148–155
  47. Kreitman RJ, Margulies I, Stetler-Stevenson M, et al. Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) towards fresh malignant cells from patients with B-cell leukemias. Clinical Cancer Research. 2000;6:1476–1487
  48. Kreitman RJ, Squires DR, Stetler-Stevenson M, et al. Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. Journal of Clinical Oncology. 2005;23:6719–6729
  49. Kreitman RJ, Wilson WH, Bergeron K, et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. The New England Journal of Medicine. 2001;345:241–247
  50. Cheson BD, Martin A. Clinical trials in hairy cell leukemia. Current status and future directions. [published erratum appears in Ann Intern Med 1987 Oct;107(4):604] Annals of Internal Medicine. 1987;106:871–878
  51. Bouroncle BA, Wiseman BK, Doan CA. Leukemic reticuloendotheliosis. Blood. 1958;13:609–630
  52. Katayama I, Li CY, Yam LT. Histochemical study of acid phosphatase isoenzyme in leukemic reticuloendotheliosis. Cancer. 1972;29:157–164
  53. Golomb HM, Catovsky D, Golde DW. Hairy cell leukemia: a clinical review based on 71 cases. Annals of Internal Medicine. 1978;89:677–683
  54. Hassan IB, Hagberg H, Sundstrom C. Immunophenotype of hairy-cell leukemia. European Journal of Haematology. 1990;45:172–176
  55. Robbins BA, Ellison DJ, Spinosa JC, et al. Diagnostic application of two-color flow cytometry in 161 cases of hairy cell leukemia. Blood. 1993;82:1277–1287
  56. DelGiudice I, Matutes E, Morilla R, et al. The diagnostic value of CD123 in B-cell disorders with hairy or villous lymphocytes. Haematologica. 2004;89:303–308
  57. Blasinska-Morawiec M, Robak T, Krykowski E, et al. Hairy cell leukemia-variant treated with 2-chlorodeoxyadenosine – a report of three cases. Leukemia & Lymphoma. 1997;25:381–385
  58. Dunn P, Shih LY, Ho YS, et al. Hairy cell leukemia variant. Acta Haematologica. 1995;94:105–108
  59. Wu ML, Kwaan HC, Goolsby CL. Atypical hairy cell leukemia. Archives of Pathology & Laboratory Medicine. 2000;124:1710–1713
  60. Else M, Ruchlemer R, Osuji N, et al. Long remissions in hairy cell leukemia with purine analogs - a report of 219 patients with a median follow-up of 12.5 years. Cancer. 2005;104:2442–2448
  61. Chadha P, Rademaker AW, Mendiratta P, et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience. Blood. 2005;106:241–246
  62. Goodman GR, Burian C, Koziol JA, et al. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. Journal of Clinical Oncology. 2003;21:891–896
  63. Saven A, Burian C, Koziol JA, et al. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood. 1998;92:1918–1926
  64. Filleul B, Delannoy A, Ferrant A, et al. A single course of 2-chloro-deoxyadenosine does not eradicate leukemic cells in hairy cell leukemia patients in complete remission. Leukemia. 1994;8:1153–1156
  65. Carbone A, Reato G, Di Celle PF, et al. Disease eradication in hairy cell leukemia patients treated with 2- chlorodeoxyadenosine [letter]. Leukemia. 1994;8:2019–2020
  66. Tallman MS, Hakimian D, Kopecky KJ, et al. Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2- deoxycoformycin and prediction of early relapse. Clinical Cancer Research. 1999;5:1665–1670
  67. Seymour JF, Kurzrock R, Freireich EJ, et al. 2-chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia. Blood. 1994;83:2906–2911
  68. Seymour JF, Talpaz M, Kurzrock R. Response duration and recovery of CD4+ lymphocytes following deoxycoformycin in interferon-alpha-resistant hairy cell leukemia: 7- year follow-up. Leukemia. 1997;11:42–47
  69. Zinzani PL, Ascani S, Piccaluga PP, et al. Efficacy of rituximab in hairy cell leukemia treatment. Journal of Clinical Oncology. 2000;18:3875–3877
  70. Hagberg H. Chimeric monoclonal anti-CD20 antibody (rituximab) – an effective treatment for a patient with relapsing hairy cell leukaemia. Medical Oncology. 1999;16:221–222
  71. Hoffman M, Auerbach L. Bone marrow remission of hairy cell leukaemia induced by rituximab (anti-CD20 monoclonal antibody) in a patient refractory to cladribine. British Journal of Haematology. 2000;109:900–901
  72. Sokol L, Agosti SJ. Simultaneous manifestation of chronic lymphocytic leukemia (CLL) and hairy cell leukemia (HCL). American Journal of Hematology. 2004;75:107–109
  73. Pollio F, Pocali B, Palmieri S, et al. Rituximab: a useful drug for a repeatedly relapsed hairy cell leukemia patient. Annals of Hematology. 2002;81:736–738
  74. Hagberg H, Lundholm L. Rituximab, a chimaeric anti-CD20 monoclonal antibody, in the treatment of hairy cell leukaemia. British Journal of Haematology. 2001;115:609–611
  75. Lauria F, Lenoci M, Annino L, et al. Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia. Haematologica. 2001;86:1046–1050
  76. Nieva J, Bethel K, Saven A. Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia. Blood. 2003;102:810–813
  77. Thomas DA, O'Brien S, Bueso-Ramos C, et al. Rituximab in relapsed or refractory hairy cell leukemia. Blood. 2003;102:3906–3911
  78. Moake JL. Thrombotic microangiopathies. The New England Journal of Medicine. 2002;347:589–600
  79. Salvatore G, Beers R, Margulies I, et al. Improved cytotoxic activity towards cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display. Clinical Cancer Research. 2002;8:995–1002
  80. Decker T, Oelsner M, Kreitman RJ, et al. Induction of caspase-dependent programmed cell death in B-cell chronic lymphocytic leukemia cells by anti-CD22 immunotoxins. Blood. 2004;103:2718–2726
  81. Ho M, Kreitman RJ, Onda M, et al. In vitro antibody evolution targeting germline hot spots to increase activity of an anti-CD22 immunotoxin. The Journal of Biological Chemistry. 2004;280:607–617
  82. Arons E, Margulies I, Sorbara L, et al. Minimal residual disease in hairy cell leukemia patients assessed by clone-specific PCR. Clinical Cancer Research. 2006;12:2804–2811

PII: S1521-6926(06)00045-4

doi: 10.1016/j.beha.2006.06.009

Best Practice & Research Clinical Haematology
Volume 19, Issue 4 , Pages 685-699 , December 2006

Article Tools

* Image Usage & Resolution